The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Rachel N. Grisham
No relevant relationships to disclose
Evis Sala
No relevant relationships to disclose
Qin Zhou
No relevant relationships to disclose
Alexia Iasonos
No relevant relationships to disclose
Deborah DeLair
No relevant relationships to disclose
Gopa Iyer
No relevant relationships to disclose
David Michael Hyman
No relevant relationships to disclose
David R. Spriggs
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose